Targeting Regulatory T Cells to Remodel Peripheral Immune Tolerance: Research Advances and Future Directions

ZHANG Wei, LI Zhenhong, LIANG Hantian, CHENG Hao, ZHANG Dunfang

Abstract

Regulatory T cells (Tregs) are the most important population of immune cells in maintaining peripheral immune tolerance in the body. Targeting Tregs to rebuild peripheral immune tolerance has shown broad potential for application in the treatment of various inflammatory diseases, such as autoimmune diseases, allergic disorders, graft-versus-host disease, and organ transplant rejection. However, substantial challenges remain in translating Treg-based therapies into clinical practice. In this review, we first summarize the discovery of Tregs and the principal mechanisms through which Tregs inhibit immune responses. Then, the research progress in polyclonal Treg-based therapy, antigen-specific Treg-based therapy, and low-dose interleukin-2 (IL-2) therapy and the implementation status of clinical trials of Treg therapies were comprehensively summarized. Finally, four issues, including maintaining the stability of Tregs, preparing autoantigen-specific Tregs, such as chimeric antigen receptor (CAR)-Tregs and T-cell receptor (TCR)-Tregs, reshaping the inflammatory microenvironment of diseases, and minimizing the potential adverse effects of Treg therapies, were highlighted as the bottleneck problems in the clinical translation of Treg therapies and priority directions for future research.

 

Keywords: Regulatory T cell therapy, Immunotherapy, Autoimmune diseases, Graft-versus-host disease, Foxp, Low-dose interleukin-2 therapy, Review

 

Full Text:

PDF


References


SONG X, LIANG H, NAN F, et al. Autoimmune diseases: molecular pathogenesis and therapeutic targets. MedComm, 2025, 6(7): e70262. doi: 10.1002/mco2.70262.

SAKAGUCHI S, MIKAMI N, WING J B, et al. Regulatory T cells and human disease. Annu Rev Immunol, 2020, 38: 541-566. doi: 10.1146/annurev-immunol-042718-041717.

SAKAGUCHI S, SAKAGUCHI N, ASANO M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995, 155(3): 1151-1164. doi: 10.4049/jimmunol.155.3.1151.

SAKAGUCHI S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 2000, 101(5): 455-458. doi: 10.1016/s0092-8674(00)80856-9.

BRUNKOW M E, JEFFERY E W, HJERRILD K A, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 2001, 27(1): 68-73. doi: 10.1038/83784.

HORI S, NOMURA T, SAKAGUCHI S. Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299(5609): 1057-1061. doi: 10.1126/science.1079490.

FONTENOT J D, GAVIN M A, RUDENSKY A Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 2003, 4(4): 330-336. doi: 10.1038/ni904.

KHATTRI R, COX T, YASAYKO S A, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol, 2003, 4(4): 337-342. doi: 10.1038/ni909.

CHEN W, JIN W, HARDEGEN N, et al. Conversion of peripheral CD4+CD25－ naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 2003, 198(12): 1875-1886. doi: 10.1084/jem.20030152.

SHEVACH E M, THORNTON A M. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev, 2014, 259(1): 88-102. doi: 10. 1111/imr.12160.

CHEN W, KONKEL J E. Development of thymic Foxp3(+) regulatory T cells: TGF-beta matters. Eur J Immunol, 2015, 45(4): 958-965. doi: 10. 1002/eji.201444999.

SAVAGE P A, KLAWON D E J, MILLER C H. Regulatory T cell development. Annu Rev Immunol, 2020, 38: 421-453. doi: 10.1146/annurev-immunol-100219-020937.

CHEN K Y, KIBAYASHI T, GIGUELAY A, et al. Genome-wide CRISPR screen in human T cells reveals regulators of FOXP3. Nature, 2025, 642(8066): 191-200. doi: 10.1038/s41586-025-08795-5.

NAIR V S, SONG M H, KO M, et al. DNA demethylation of the Foxp3 enhancer is maintained through modulation of ten-eleven-translocation and DNA methyltransferases. Mol Cells, 2016, 39(12): 888-897. doi: 10. 14348/molcells.2016.0276.

GOSWAMI T K, SINGH M, DHAWAN M, et al. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders -Advances and challenges. Hum Vaccin Immunother, 2022, 18(1): 2035117. doi: 10.1080/21645515.2022.2035117.

PANDIYAN P, ZHENG L, ISHIHARA S, et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol, 2007, 8(12): 1353-1362. doi: 10.1038/ni1536.

MENG X, YANG J, DONG M, et al. Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol, 2016, 13(3): 167-179. doi: 10.1038/nrcardio. 2015.169.

WORTHINGTON J J, KELLY A, SMEDLEY C, et al. Integrin alphavbeta8-mediated TGF-beta activation by effector regulatory T cells is essential for suppression of T-cell-mediated inflammation. Immunity, 2015, 42(5): 903-915. doi: 10.1016/j.immuni.2015.04.012.

DEAGLIO S, DWYER K M, GAO W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med, 2007, 204(6): 1257-1265. doi: 10.1084/jem.20062512.

CAO X, CAI S F, FEHNIGER T A, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity, 2007, 27(4): 635-646. doi: 10.1016/j.immuni.2007.08.014.

ZHANG D, TU E, KASAGI S, et al. Manipulating regulatory T cells: a promising strategy to treat autoimmunity. Immunotherapy, 2015, 7(11): 1201-1211. doi: 10.2217/imt.15.79.

RAFFIN C, VO L T, BLUESTONE J A. T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol, 2020, 20(3): 158-172. doi: 10.1038/s41577-019-0232-6.

SAMY E T, PARKER L A, SHARP C P, et al. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med, 2005, 202(6): 771-781. doi: 10.1084/jem.20041033.

DIPAOLO R J, GLASS D D, BIJWAARD K E, et al. CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol, 2005, 175(11): 7135-7142. doi: 10.4049/jimmunol.175.11.7135.

MORGAN M E, FLIERMAN R, VAN DUIVENVOORDE L M, et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum, 2005, 52(7): 2212-2221. doi: 10.1002/art.21195.


Refbacks

  • There are currently no refbacks.